|Videos|April 10, 2020
Weekly Webinar Series Part 5: Managing Lung Cancer Patients Through the COVID-19 Pandemic
Advertisement
Episodes in this series
In part 5 of our weekly COVID-19 Webinar Series, Nathan Pennell, MD, PhD; Stephen Liu, MD; Charu Aggarwal, MD, MPH; H. Jack West, MD; with special guest speaker, Miriam A Knoll, MD, DABR; will share the latest updates and insights on the novel coronavirus. The webinar covers key information regarding:
- Evolving radiation strategies in the era of COVID-19
- How recently updated guidelines impact use of radiation
- Management of physician and healthcare worker wellness and stress
- Case-based discussions in COVID-19—positive patients
Advertisement
Related to this article
Roswell Park Comprehensive Cancer Center broke ground on an expansion of the Roswell Park Broadview Community Outreach and Engagement Center.
A prespecified analysis showed benefit with anselamimab in patients with kappa light chain AL amyloidosis.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The selective BCR::ABL1 inhibitor ELVN-001 produced major molecular responses in previously treated chronic-phase CML, including after asciminib progression.
Actinomycin D plus low-dose cytarabine and venetoclax produced high remission rates in a retrospective cohort of patients with NPM1-mutated AML.
Revumenib added to intensive chemotherapy produced deep, MRD-negative remissions with a manageable safety profile in newly diagnosed AML.
Ofirnoflast produced hematologic improvement in two-thirds of patients with ESA-refractory lower-risk MDS.
Mayo Clinic researchers identified a potential new approach to treating glioblastoma to improve the effectiveness of existing chemotherapy.
Advertisement
Advertisement
Trending on OncLive
1
Ofirnoflast Elicits Durable Transfusion Independence, Hematologic Improvement in Lower-Risk MDS
2
Revumenib Plus Chemo Yields High Response and MRD-Negativity Rates in Newly Diagnosed NPM1+ or KMT2A+ AML
3
ACTIVE Regimen Elicits High Response Rates in R/R NPM1-Mutated AML
4
Dr Gangat on Phase 2 Efficacy and Safety Data for DISC-3405 in Polycythemia Vera
5